ArticlePloS one2022

Correction: Infliximab for pediatric patients with Crohn's disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan.

Hitoshi Tajiri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.